Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
作者： M.C. Garassino , M. Marabese , P. Rusconi , E. Rulli , O. Martelli
关键词:
摘要: … 1.5%, G13D 6.2%, G13C 3.1%, G12R 1.5% and G12F 1.5%). In particular, we found that G12C is the most expressed mutation in lung cancer, while in colon cancer, G12D is the most …
annalsofoncology.org
oup.com
oxfordjournals.org
elsevier.com
paperity.org参考文章(5)
Hans Prenen, Sabine Tejpar, Eric Van Cutsem, New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer: Fig. 1. Clinical Cancer Research. ,vol. 16, pp. 2921- 2926 ,(2010) , 10.1158/1078-0432.CCR-09-2029
C. Ferté, B. Besse, E. Dansin, F. Parent, M.-P. Buisine, M.-C. Copin, N. Penel, J.-C. Soria, Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. Annals of Oncology. ,vol. 21, pp. 1385- 1387 ,(2010) , 10.1093/ANNONC/MDQ153
Manickam Janakiraman, Efsevia Vakiani, Zhaoshi Zeng, Christine A. Pratilas, Barry S. Taylor, Dhananjay Chitale, Ensar Halilovic, Manda Wilson, Kety Huberman, Julio Cezar Ricarte Filho, Yogindra Persaud, Douglas A. Levine, James A. Fagin, Suresh C. Jhanwar, John M. Mariadason, Alex Lash, Marc Ladanyi, Leonard B. Saltz, Adriana Heguy, Philip B. Paty, David B. Solit, Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer Cancer Research. ,vol. 70, pp. 5901- 5911 ,(2010) , 10.1158/0008-5472.CAN-10-0192
Patrick J. Roberts, Thomas E. Stinchcombe, Channing J. Der, Mark A. Socinski, Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy? Journal of Clinical Oncology. ,vol. 28, pp. 4769- 4777 ,(2010) , 10.1200/JCO.2009.27.4365
Astrid Lièvre, Jean-Baptiste Bachet, Delphine Le Corre, Valérie Boige, Bruno Landi, Jean-François Emile, Jean-François Côté, Gorana Tomasic, Christophe Penna, Michel Ducreux, Philippe Rougier, Frédérique Penault-Llorca, Pierre Laurent-Puig, KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer Cancer Research. ,vol. 66, pp. 3992- 3995 ,(2006) , 10.1158/0008-5472.CAN-06-0191